Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

19 Mar 2018

Abstract excerpt

Abstract Purpose: Persistent androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic strategies to overcome this are urgently required. We evaluated how bromodomain and extra-terminal (BET) protein inhibitors (BETi) abrogate aberrant AR signaling in CRPC. Experimental Design: We determined associations between BET...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29555663
DOI: 10.1158/1078-0432.ccr-17-3571

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)PMID 29555663Read ↗

BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancerSemantic proximity Read ↗

Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.Semantic proximity Read ↗

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerSemantic proximity Read ↗

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinationsSemantic proximity Read ↗

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate CancerSemantic proximity Read ↗

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerSemantic proximity Read ↗

BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancerSemantic proximity Read ↗

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancerSemantic proximity Read ↗

Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

The Silver Lining in BET Protein Targeting for Advanced Prostate Cancer Pharmacotherapy: Recent UpdatesSemantic proximity Read ↗

BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.